AI Patient Stratification & Predictive Biomarkers for CROs
CROs must shift from data to strategic insights. MyImmune’s computational immunology platform lets you launch high-margin precision medicine services and de-risk biotech assets seamlessly.
The "Zero-CapEx" Innovation Layer
Unlike hardware-heavy competitors, MyImmune is a software-only solution. It integrates directly into your existing NGS workflows, enabling you to launch premium predictive biomarker reports without capital expenditure on new lab equipment.
Transform Data into High-Margin Services
Stop competing on the price of raw FASTQ files. Elevate basic, low-margin sequencing data into actionable predictive insights. This empowers you to charge premium rates for advanced biomarker stratification and target validation services without changing your wet-lab operations.
Retain Client Ownership
Centralized competitors (like Adaptive Biotechnologies) force you to send samples to their proprietary labs, capturing your sequencing revenue. MyImmune’s decentralized architecture allows you to run analyses entirely in-house. You keep the wet-lab revenue, maintain strict sample chain-of-custody, and own the pharma relationship end-to-end.
Unmatched Accuracy via Paratope Resolution
Traditional clonotyping relies on genetic lineage, missing functional connections and requiring massive cohorts. By clustering B and T cell receptors based on what they bind to (paratopes), MyImmune identifies shared immune signatures across diverse patient populations.
This biological resolution delivers benchmark-beating therapy response predictions. Empower your sponsors to enrich trial populations, increase their Probability of Technical and Regulatory Success (PTRS), or retrospectively rescue failing Phase II trials.
Launch Your AI Biomarker Service
Transform basic NGS data into premium predictive insights. Contact us or schedule an appointment to establish a Zero-CapEx partnership, retain custody, and de-risk client trials.